A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies

This study aimed to determine the maximum-tolerated dose and dose-limiting toxicities of pegylated liposomal doxorubicin (PLD) in combination with temsirolimus (T) in patients with refractory solid tumors. Using a standard “3+3” dose escalation design, 23 patients were enrolled in three dosing cohor...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Wang-Gillam, Andrea, Thakkar, Nilay, Lockhart, A. Craig, Williams, Kerry, Baggstrom, Maria, Naughton, Michael, Suresh, Rama, Ma, Cynthia, Tan, Benjamin, Lee, Wooin, Jiang, Xuntian, Mwandoro, Tibu, Trull, Lauren, Belanger, Stefanie, Creekmore, Allison N., Gao, Feng, Fracasso, Paula M., Picus, Joel
Format: Artigo
Langue:Inglês
Publié: Springer Berlin Heidelberg 2014
Sujets:
Clinical Trial Report
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4112045/
https://ncbi.nlm.nih.gov/pubmed/24916546
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-014-2493-x
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires